Fetzer, M. N. A. | bioRxiv Science

bioRxiv2026

Mimosa pudica-derived zinc oxide nanoparticles preserve mesenchymal stromal cell viability, morphology, and osteogenic competence

IntroductionMusculoskeletal disorders remain a major cause of disability worldwide and require non invasive regenerative strategies that support tissue repair. Green-synthesized zinc oxide nanoparticles (ZnONPs) have attracted interest because of their biocompatibility and biological activity. This study investigated the synthesis of Mimosa pudica-derived ZnONPs (ZnOMP) and evaluated their effects on human bone marrow mesenchymal stromal cells (BM-MSCs). MethodologyZnOMP were synthesized using an aqueous extract of Mimosa pudica leaves and characterized by UV-Vis spectroscopy, FTIR spectroscopy, powder X-ray diffraction, SEM, EDS, and TEM. BM-MSCs isolated from human bone marrow were exposed to ZnOMP, plant extract, and synthesized ZnO nanoparticles. Cell metabolic activity was assessed by MTT assay after 1, 3, and 5 days. Cytoskeletal and nuclear morphology were analyzed by fluorescence microscopy and CellProfiler-based morphometry. Osteogenic differentiation was evaluated after 21 days using Alizarin Red S staining and quantification. ResultsSpectroscopic and microscopic analyses confirmed the successful formation of phytochemical-capped ZnOMP nanoparticles with nanoscale dimensions and specific elemental composition. ZnOMP maintained significantly higher metabolic activity than Mimosa pudica extract or ZnO at both 150 and 300 g/mL. Morphometric profiling revealed that Mimosa pudica extract induced the most pronounced changes in nuclear morphology, reflecting enhanced nuclear plasticity and substantial remodeling of nuclear architecture, whereas ZnOMP preserved cellular and nuclear features closer to untreated controls. During osteogenic induction, ZnOMP did not impair matrix mineralization and preserved the ability of BM-MSCs to form a mineralized extracellular matrix. ConclusionMimosa pudica-mediated ZnO nanoparticles combine favorable biocompatibility with preservation of mesenchymal stem cell morphology and osteogenic competence. These findings support their potential use as bioactive nanomaterials for musculoskeletal tissue engineering and regenerative medicine.

pharmacology and toxicology↗

bioRxiv2024

Chitosan nanocapsules with Alstonia boonei extract modulate the immune system in Wistar rats

The development of biosynthetic methods for nanoparticles using plants presents an exciting opportunity to better utilize our rich and diverse medicinal flora. We are particularly interested in creating nanocapsules using Alstonia boonei, a Cameroonian plant known for its immunomodulatory properties. Chitosan nanocapsules were synthesized from the methanol/dichloromethane extract of the powdered stem bark of A. boonei after harvest and drying. The encapsulation of the secondary metabolites was achieved using the ionic gelation method, which involved the agitation of a chitosan solution, extract, and tripolyphosphate. Subsequently, the encapsulation efficiency was calculated. Infrared spectroscopy identified the various functional groups present in the nanocapsules. The acute toxicological profile of these chitosan nanocapsules at a limit dose of 2000 mg/kg, along with their immunomodulatory activities, was evaluated in Wistar rats. The immunomodulatory potential was assessed in dexamethasone-induced immunosuppressed rats by measuring total blood count, delayed-type hypersensitivity response, and hemagglutinating antibody titre between groups of animals after 14 days of treatment. The data collected on the synthesis and characterization confirmed the formation of nanocapsules. This was evidenced by infrared spectroscopy and an entrapment efficiency of 69%. Powder X-ray diffraction confirmed the presence of chitosan in the polymer material. SEM imaging further confirmed the formation of nanocapsules. The toxicological profile of these nanocapsules was found to be satisfactory. Administration of chitosan nanocapsules containing Al. boonei methanol/dichloromethane extracts at doses of 100 mg/kg, 200 mg/kg, and 500 mg/kg body weight significantly prevented dexamethasone-induced immunosuppression in rats. This was achieved by increasing the parameters of total blood count (hematocrit, mean corpuscular volume, platelets, lymphocytes, and granulocyte counts), hemagglutinating antibody titre values, and delayed type hypersensitivity response induced by chicken red blood cells. However, doses of 500 mg/kg of crude A. boonei extract and 500 mg/kg body weight of empty chitosan nanocapsules did not show this effect. The nanocapsules generated from the extracts of chitosan and A. boonei are responsible for immunostimulatory activity and possess therapeutic potentials for the prevention of depressed immune depressed conditions with satisfactory safety at acute dose.

pharmacology and toxicology↗